Načítá se...
PD-L1 in melanoma: facts and myths
The use of monoclonal antibodies that block immunologic checkpoints that would otherwise mediate the adaptive immune resistance have paved the way in cancer treatment. There is evidence that blocking the PD-1/PD-L1 axis is a strategy of overriding importance in the treatment of patients with metasta...
Uloženo v:
| Vydáno v: | Melanoma Manag |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Future Medicine Ltd
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6096437/ https://ncbi.nlm.nih.gov/pubmed/30190888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/mmt-2016-0013 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|